Abstract
The novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing COVID-19 has rapidly turned into a pandemic, infecting millions and causing ~7 million deaths across the globe. In addition to studying the mode of transmission and evasion of host immune system, analysing the viral mutational landscape constitutes an area under active research. The latter is expected to impart knowledge on the emergence of different clades, subclades, viral protein functions and protein-protein and protein–RNA interactions during replication/transcription cycle of virus and response to host immune checkpoints. In this study we have attempted to bring forth the viral genomic variants defining the major clade(s) as identified from samples collected from the state of Telangana, India.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Not applicable
Funding Statement
We thank the Telangana State Government, the Indian Council of Medical Research, Government of India, the University of Hyderabad, Hyderabad and CDFD, Hyderabad, for procurement of consumables and equipment to perform screening of patient samples and the Department of Biotechnology, Government of India for financial support through the National Genomics Core project (BT/INF/22/SP28169/2019,07/03/2019). R.S. acknowledges funding support from NCBS-TIFR and Ramanujan Fellowship (SB/S2/RJN-071/2018). A.G. acknowledges funding support from Science and Engineering Research Board, Department of Science and Technology (DST-SERB) in the form of National-Postdoctoral Fellowship (N-PDF).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CDFD institute bioethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The sequence data is being deposited into the GISAID database
